Helios Technologies, Inc. — FY 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022; the comparable fiscal year ended January 1, 2022. Figures are in U.S. dollars unless noted. The filing reports annual results, not standalone fourth-quarter results.
Business context
Helios designs and manufactures motion-control and electronic-control products through its Hydraulics and Electronics segments, serving industrial, mobile, recreational, marine, and health-and-wellness markets. Its strategy emphasizes organic growth, acquisitions, cross-segment system sales, innovation, and global manufacturing. Hydraulics represented 62% of 2022 sales.
2022 acquisitions included Taimi and Daman. In January 2023, after year-end, Helios acquired Schultes for initial net cash consideration of $85.0 million.
Financial performance and liquidity
| Metric | FY 2022 | Prior year | Change |
|---|---|---|---|
| Net sales | $885.4 million | $869.2 million | +1.9% |
| Gross profit / margin | $298.5 million / 33.7% | $312.8 million / 36.0% | Profit −4.6%; margin −2.3 points |
| Operating income / margin | $137.3 million / 15.5% | $149.3 million / 17.2% | Income −8.0%; margin −1.7 points |
| Net income | $98.4 million | $104.6 million | −5.9% |
| Diluted EPS | $3.02 | $3.22 | −6.2% |
| Operating cash flow | $109.9 million | $113.1 million | −$3.2 million |
| Capital expenditures | $31.9 million | $26.8 million | +19.0% |
Sales growth included $24.9 million from acquisitions, while organic sales declined $8.7 million. Pricing added $40.2 million; unfavorable currency reduced sales by $27.6 million, and supply constraints delayed an estimated $12.3 million of sales.
Segments: Hydraulics sales were $551.3 million (+6.8%), operating income was $122.7 million (+2.4%), and operating margin was 22.3% versus 23.2%. Electronics sales were $334.1 million (−5.3%), operating income was $52.5 million (−26.8%), and operating margin was 15.7% versus 20.3%.
At year-end, cash was $43.7 million, total debt was approximately $447 million, and available revolving credit was $138.8 million. The company also cited a conditional $300 million accordion feature. Debt maturities are concentrated in 2025, when $401.3 million is scheduled. Interest rates on credit facilities ranged from 3.9% to 6.4% at year-end. The company reported compliance with its credit covenants.
Inventory was $191.6 million, up 15.7% from year-end 2021; inventory days increased to 111 from 91. The quarterly dividend was $0.09 per share, or $0.36 for the year. The board intended to maintain the $0.09 quarterly dividend during 2023, subject to its discretion.
Material changes and management commentary
- Lower sales volume, higher material costs, and unfavorable currency reduced gross profit. Pricing did not fully offset material-cost inflation; material costs as a percentage of sales, excluding pricing and acquisition effects, rose 3.3 percentage points company-wide.
- Hydraulics benefited from demand, pricing, and acquisitions, while Electronics was pressured by a sharp health-and-wellness downturn and elevated customer channel inventory. Electronics sales in APAC fell 50.7%, mainly reflecting weaker wellness demand in China.
- Restructuring costs totaled $5.2 million, including manufacturing consolidation in EMEA and workforce changes in APAC and Electronics. Management said the actions are intended to improve the cost structure.
- Net income benefited from a lower tax provision (19.2% effective rate versus 20.3%), foreign-currency transaction gains, and gains on asset sales. Acquisition-related amortization declined, while restructuring and M&A-related costs weighed on operating results.
- Cash from operations decreased modestly. Working-capital movements benefited from receivables and inventory cash flows versus the prior year, but inventory remained elevated amid early purchasing, delayed components, and customer order delays.
Outlook, risks, and unusual items
Management’s stated strategic target was more than $1 billion in sales and an adjusted EBITDA margin of approximately 25% on a run-rate basis ending in fourth-quarter 2023. These are targets, not reported results or a guarantee; the filing provides no specific 2023 revenue or earnings guidance. Management forecast 2023 capital expenditures of approximately 3%–5% of sales.
Risks highlighted include cyclical demand, inflation and inability to recover higher costs through pricing, supply-chain and component constraints, foreign-exchange and variable-rate debt exposure, acquisition integration and execution, competition, and geopolitical and regulatory uncertainty. The Russia-Ukraine conflict increased energy, commodity, and logistics volatility; less than 1% of sales were to customers in Russia and Ukraine. China COVID-related shutdowns affected operations and sales through May 2022, while component sourcing constraints continued into 2023.
Interest-rate sensitivity disclosure: a one-percentage-point increase in the reference average rate would have increased 2022 financing costs by approximately $1.7 million, after swaps. A 10% decline in relevant average exchange rates was estimated to reduce annual sales by $32.6 million and net income by $8.1 million.
Other items to monitor include $6.7 million of contingent acquisition consideration payable through 2024; a building purchase commitment of €26.7 million, reduced by 60% of lease payments; and open supplier purchase orders of $131.2 million for 2023 and $15.2 million for 2024. Routine litigation was not expected to materially affect results. The company disclosed no material off-balance-sheet financing arrangements. The auditor issued unqualified opinions on the financial statements and internal controls; no critical audit matters were identified.
Important facts for investors to verify
- Whether organic demand, especially in health and wellness and APAC, stabilized and whether delayed supply-constrained sales converted to revenue.
- Whether pricing and productivity measures recovered input-cost inflation and improved margins from 2022 levels.
- Whether inventory declined from its elevated level and working capital converted into cash.
- Progress toward the stated 2023 sales and adjusted EBITDA margin targets; the filing does not report actual adjusted EBITDA for FY 2022 in the supplied text.
- Debt repayment, interest expense, covenant headroom, and liquidity after the Schultes acquisition and the 2025 maturity concentration.
- Integration, purchase-price allocation, and returns from Daman, Taimi, and Schultes, including the preliminary Daman valuation and Schultes post-closing adjustment.
- Whether the board maintained the stated quarterly dividend and whether acquisition, capital spending, or economic conditions changed liquidity priorities.